Smith & Nephew SNATS, Inc. (NYSE:SNN) to Issue $0.29 Semi-annual Dividend

Key Points

• Smith & Nephew SNATS, Inc. declared a semi-annual dividend of $0.29 to be distributed to shareholders on November 7th, with a dividend yield of 210.0%.
• The company has a dividend payout ratio of 42.0%, indicating strong coverage of its dividend by earnings, with expected future earnings allowing for continued dividend payments.
• Smith & Nephew's stock has been rated as a "hold" by multiple analysts, with a current market capitalization of $15.53 billion and a consensus target price of $28.00.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) declared a semi-annual dividend on Wednesday, August 6th, Wall Street Journal reports. Shareholders of record on Friday, October 3rd will be given a dividend of 0.285 per share by the medical equipment provider on Friday, November 7th. This represents a dividend yield of 210.0%. The ex-dividend date is Friday, October 3rd.

Smith & Nephew SNATS has a dividend payout ratio of 42.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Smith & Nephew SNATS to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.92 annual dividend with an expected future payout ratio of 46.0%.

Smith & Nephew SNATS Stock Down 0.1%

NYSE SNN traded down $0.03 during trading hours on Wednesday, hitting $35.46. The company's stock had a trading volume of 1,348,086 shares, compared to its average volume of 899,509. Smith & Nephew SNATS has a 52 week low of $23.69 and a 52 week high of $35.88. The company has a current ratio of 2.89, a quick ratio of 1.33 and a debt-to-equity ratio of 0.62. The company's 50-day simple moving average is $30.15 and its two-hundred day simple moving average is $28.24. The company has a market capitalization of $15.53 billion, a PE ratio of 16.41, a price-to-earnings-growth ratio of 0.94 and a beta of 0.68.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Hsbc Global Res lowered Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Smith & Nephew SNATS currently has a consensus rating of "Hold" and a consensus target price of $28.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.